17:59 , Oct 12, 2018 |  BC Week In Review  |  Company News

Arbutus falls on HBV program updates

Arbutus Biopharma Corp. (NASDAQ:ABUS) lost $3.09 (34%) to $6 on Oct. 9 after announcing updates for two of its HBV programs. The move translated to a loss of over $170 million in the company's market...
23:50 , Oct 9, 2018 |  BC Extra  |  Clinical News

Arbutus falls on HBV program updates

Arbutus Biopharma Corp. (NASDAQ:ABUS) lost $3.09 (34%) to $6 on Tuesday after announcing updates for two of its HBV programs. The move translated to a loss of over $170 million in the company's market cap....
00:42 , Aug 12, 2017 |  BioCentury  |  Product Development

HBV test kitchen

Early results for HBV monotherapies are pointing the way toward combinations that could deliver a functional cure. What remains unknown is how many components, and which ones, will prove necessary to eliminate remnants of the...